Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 491-497, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bonfrer, J. M. G.
Right arrow Articles by Kenemans, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bonfrer, J. M. G.
Right arrow Articles by Kenemans, P.
Related Collections
Right arrow Laboratory Management
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1997;43:491-497.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value

Johannes M. G. Bonfrer1,a, Catharina M. Korse1, Rob A. Verstraeten2, Gerard J. van Kamp3, Guus A. M. Hart4 and Peter Kenemans2

1 Departments of Clinical Chemistry and
4 Statistics, The Netherlands Cancer Institute (Antoni van Leeuwenhoek Huis), Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

2 Departments of Obstetrics and Gynecology and
3 Clinical Chemistry, Academic Hospital Free University, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
a Author for correspondence. Fax +31 20 6172625.

The Byk LIA-mat CA125 II assay was compared with the Centocor IRMA CA125 II. Serum samples studied (n = 1012) were obtained from 652 apparently healthy females, 61 pregnant women, and 299 patients with benign and malignant gynecological tumors. The CA125 II assay value at the 95th percentile of the total healthy group was 29 kU/L for the LIA-mat and 32 kU/L for the Centocor assay. For the LIA-mat assay the 95th percentile was 31 kU/L (Centocor 36 kU/L) for the group <45 years and 21 kU/L (Centocor 25 kU/L) for women >55 years of age. By using ROC curves we found the optimal pretreatment Byk LIA-mat CA125 II value differentiating between benign and malignant ovarian tumors to be 95 kU/L. Pretreatment CA125 values >1000 kU/L were detected in serum samples of patients with advanced epithelial ovarian cancer.


Key Words: indexing terms: tumor marker • immunoassay • gynecological neoplasms




The following articles in journals at HighWire Press have cited this article:


Home page
 JCOHome page
A. Santillan, R. Garg, M. L. Zahurak, G. J. Gardner, R. L. Giuntoli II, D. K. Armstrong, and R. E. Bristow
Risk of Epithelial Ovarian Cancer Recurrence in Patients With Rising Serum CA-125 Levels Within the Normal Range
J. Clin. Oncol., December 20, 2005; 23(36): 9338 - 9343.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.